Merck acquires Terns Pharmaceuticals

Merck has announced the acquisition of Terns Pharmaceuticals for approximately $6.7 billion, marking a strategic move to enhance its oncology pipeline. This all-cash transaction focuses on securing TERN-701, a promising oral treatment targeting chronic myeloid leukemia (CML), a niche yet impactful segment of the leukemia market. Positioned at $53 per share, the acquisition represents a 6% premium over Terns' previous closing price, valuing Terns at $5.7 billion excluding its $1 billion in cash reserves.

At the heart of the acquisition is TERN-701, an innovative BCR::ABL tyrosine kinase inhibitor, which has showcased positive results in early-phase trials. The treatment aims to provide an effective solution for patients with the Philadelphia chromosome-positive form of CML, particularly those who have experienced treatment failures with other TKIs. TERN-701's potential to reshape CML treatment has raised industry interest, given its orphan drug designation by the FDA and its demonstration of major and deep molecular responses with minimal side effects.

For Merck, this acquisition is strategic, considering the looming patent expiry of its blockbuster immunotherapy Keytruda in 2028. The company is actively supplementing its oncology portfolio to mitigate future revenue impacts. Analysts see TERN-701 as a potential competitor to Novartis' Scemblix, already garnering peak sales projections of $4 billion globally. By adding TERN-701, Merck aims to not only solidify its position in the CML market but also to potentially surpass Novartis' current market share.

The acquisition plays into a broader industry context characterized by increased competition and consolidation, particularly in the oncology sector. With CML accounting for 15% of new leukemia cases and about 9,650 anticipated diagnoses in the U.S. this year, the demand for innovative treatments remains high. Merck's recent acquisitions suggest a focused strategy on bolstering its pharmaceutical pipeline, complementing respiratory and antiviral advancements with this latest foray into hematology.

Closing of the transaction is expected in the second quarter of the year, contingent upon customary regulatory approvals. The market awaits further developments on late-stage trials for TERN-701, anticipated to commence towards the year's end or early next. As Merck integrates Terns and advances TERN-701, the broader oncology competitive landscape will be closely watching the drug's potential impact on existing treatment paradigms.